Free Trial
NASDAQ:EPRX

Eupraxia Pharmaceuticals (EPRX) Stock Price, News & Analysis

Eupraxia Pharmaceuticals logo
$2.93 -0.17 (-5.52%)
Closing price 03:50 PM Eastern
Extended Trading
$2.93 +0.00 (+0.03%)
As of 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Eupraxia Pharmaceuticals Stock (NASDAQ:EPRX)

Key Stats

Today's Range
$2.92
$3.32
50-Day Range
$2.93
$4.29
52-Week Range
$2.20
$4.48
Volume
13,153 shs
Average Volume
16,262 shs
Market Capitalization
$104.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50
Consensus Rating
Strong Buy

Company Overview

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Remove Ads

Eupraxia Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

EPRX MarketRank™: 

Eupraxia Pharmaceuticals scored higher than 36% of companies evaluated by MarketBeat, and ranked 687th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Eupraxia Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Eupraxia Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Eupraxia Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Eupraxia Pharmaceuticals are expected to grow in the coming year, from ($0.67) to ($0.60) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Eupraxia Pharmaceuticals is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Eupraxia Pharmaceuticals is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Eupraxia Pharmaceuticals has a P/B Ratio of 97.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Eupraxia Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    0.55% of the float of Eupraxia Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Eupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Eupraxia Pharmaceuticals has recently decreased by 2.84%, indicating that investor sentiment is improving.
  • Dividend Yield

    Eupraxia Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Eupraxia Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.55% of the float of Eupraxia Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Eupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Eupraxia Pharmaceuticals has recently decreased by 2.84%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Eupraxia Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for EPRX on MarketBeat in the last 30 days.
Receive EPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EPRX Stock News Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Eupraxia Pharmaceuticals reports FY24 EPS (76c), consensus (63c)
Eupraxia Pharmaceuticals’ EP-104GI shows efficacy in esophagitis trial
See More Headlines

EPRX Stock Analysis - Frequently Asked Questions

Eupraxia Pharmaceuticals' stock was trading at $3.17 at the start of the year. Since then, EPRX shares have decreased by 7.6% and is now trading at $2.9290.
View the best growth stocks for 2025 here
.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) posted its earnings results on Thursday, March, 20th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.01.

Shares of EPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eupraxia Pharmaceuticals investors own include Aeterna Zentaris (AEZS), BlackBerry (BB), Bausch Health Companies (BHC), Bitfarms (BITF), Ballard Power Systems (BLDP), Cardiol Therapeutics (CRDL) and Fury Gold Mines (FURY).

Company Calendar

Last Earnings
3/20/2025
Today
4/04/2025
Next Earnings (Estimated)
4/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EPRX
Previous Symbol
NASDAQ:EPRX
Fax
N/A
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.50
High Stock Price Target
$12.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+258.5%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-28,220,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.03 per share
Price / Book
97.63

Miscellaneous

Free Float
N/A
Market Cap
$104.41 million
Optionable
N/A
Beta
N/A
7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:EPRX) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners